Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of stannsoporfin in neonates with hyperbilirubinemia
2009-017434-45Phase 2Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jan 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of stannsoporfin in neonatal hyperbilirubinemia (4 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Change in adjusted total serum bilirubin from baseline to 48 hours. Started Jan 2010; status: terminated.
02
Drugs
stannsoporfin
03
Conditions
neonatal hyperbilirubinemia
Beyond the preview
Go deeper on 2009-017434-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017434-45.